Theralase Technologies Inc. V.TLT

The number to beat is 39%CR...(for now).

[wildbird1]

We all know that the Big Pharma that will strike a deal with TLT for TLT-Ruvidar will use the "Optimized Treatment Protocol CR%" to evaluate TLT treatment potential and value($).

If you read the last email from Matthew Perraton...Under " FDA  Approved Drugs Versus Ruvidar"(blue box).
TLT said" Theralase Ruvidar estimated durable CR%(15 months) for 2026 is 39% optimized".
Note..For me 39%CR in 2026 seem to be concervative(but what do I know).

As we speak TLT-Ruvidar 15 months CR% is 36%CR optimized(36%CR is already huge if you consider that TLT-Ruvidar treat patients that other treatments can't treat).

Valrubicin, Keytruda,Adstiladrin, N803+BCG...All the above have long term CR% lower than 39%, and have either side effects(Valrubicin,Keytruda) or many restrictions(Adstiladrin,N803+BCG).

As we speak TLT-Ruvidar is the only treatment that doesn't  have side effect or restrictions and a 36-39%CR.
In short TLT-Ruvidar is the only treatment that will treat 100% of patients.

Question???
What is the $value of a Big Pharma deal for a treatment that has 36-39CR% no side effects and no restrictions and can treat 100% of patients?

We are on the verge of finding out.

[Longholder99]

Totally agree. The planning and outreach by Dr Lbiati as a member of the Board is Theralases effort on that front IMO.  I'm hopeful that we will see these results as are many here.  GLTA

[Oilminerdeluxe]

That's the kind of post I like. It put a smile on my face. A greedy one.

[StevenBirch]

Thanks Wildbird.

[99942Apophis]

I would like to tackle that question you presented wildbird1.  We must look at how much revenue the Ruvidar treatment will generate in their first year of commercialization and to be conservative lets say 15% from both Canada and US for NMIBC which for 2023 had been estimated at 90,000 patients. I personally wasn't happy with the $50k, $100k or $150k figures since we must take into

[BlueFranky]

hi Apophis Based on that hypothetical $40 billion offer, what multiple and therefore what share price would that command in a buyout?

[Alamir1111]

Too big of a nr I think around 1600$ per share?

[Alamir1111]

Shoot that would put me around1.120.000.000.not bad?

[Alamir1111]

Always wanted to be a Rockstar or pornstar with that money I can pursue my dreams

[Oilminerdeluxe]

Remover a zero... Stillgood though. I am more modest, Will be happy as long as a B is involved. A successful GBM study might help with that.

[99942Apophis]

That 40B would be for the perfect dream of NMIBC,  MIBC, vaccine,  GBM & NSCLC giving us a share price of $125.00, realistically a $40 to $60 range isn't out of the question.  I know some of my fellow posters might roll their eyes but this is highly possible! 

[Alamir1111]

What would be the timeline to achieve all this ?

[N0taP00p]

It's  easier now to see why many here are so wound up and unable to have rational conversations. It is much easier to dream up and project 20,000% to 30,000% gains and then protect that balloon from being popped by real questions around finances and timelines, for example.  When we get to $5, let's talk.  We'll have a happy starting point. 

[Alamir1111]

.50 c would be a more appropriate  starting point what you a pumpee?

[Alamir1111]

Jan 2024 .50 c warrants must be filled ??

[99942Apophis]

You've got a deal NOtaPOOp, run the North American numbers yourself  X whichever treatment charge you wish minus average cost of sales and partnership percentage then with the remaining figure reduce it by an estimated tax. Firstly though don't forget to take a low first year percentage of patients then calculate a reasonable increase of patients for say the first 5 years which should

[99942Apophis]

oops forgot subtract from gross revenue overhead ( wages, bonuses consulting fees and general expenses )

[N0taP00p]

999:  It's not too hard to conjure up complex sounding projections. Part of my work involves working with data analysts but must admit I'm not one.  One thing though, we don't know what percent of the total patient population for BCGR-NMIBC will pick Ruvidar.  Marketing dollars can sway votes where it matters.   GBM validity is still many many years out. So is

[99942Apophis]

My projected guessed numbers in the past have always been  different mainly because of possible variables and very low patient base in the first few years growing in additional years. All debit/credit figures are average percentages of research companies. As far as your question on where is the money coming from confuses me when we all know Theralase is about to pass their first major

[chry200030]

It's all here.. https://www.eurekalert.org/news-releases/592710#:~:text=Topel%2C%20two%20University%20of%20Chicago,be%20worth%20about%20%2450%20trillion.